Cargando…
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621550/ http://dx.doi.org/10.1097/01.HS9.0000890576.23258.1c |
| _version_ | 1784821583242592256 |
|---|---|
| author | Borchmann, Peter Moccia, Alden Greil, Richard Herzberg, Mark Fosså, Alexander Hüttmann, Andreas Keil, Felix Dierlamm, Judith Schaub, Valdete Hänel, Mathias Novak, Urban Meissner, Julia Hellmuth, Johannes Mathas, Stephan Zijlstra, Josée. M. Viardot, Andreas Hertenstein, Bernd Martin, Sonja Giri, Pratush Kreissl, Stefanie Fuchs, Michael Schneider, Gundolf Rosenwald, Andreas Klapper, Wolfram Eich, Hans Theodor Baues, Christian Hallek, Michael Kobe, Carsten Diehl, Volker Engert, Andreas |
| author_facet | Borchmann, Peter Moccia, Alden Greil, Richard Herzberg, Mark Fosså, Alexander Hüttmann, Andreas Keil, Felix Dierlamm, Judith Schaub, Valdete Hänel, Mathias Novak, Urban Meissner, Julia Hellmuth, Johannes Mathas, Stephan Zijlstra, Josée. M. Viardot, Andreas Hertenstein, Bernd Martin, Sonja Giri, Pratush Kreissl, Stefanie Fuchs, Michael Schneider, Gundolf Rosenwald, Andreas Klapper, Wolfram Eich, Hans Theodor Baues, Christian Hallek, Michael Kobe, Carsten Diehl, Volker Engert, Andreas |
| author_sort | Borchmann, Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621550 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215502022-11-01 T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group Borchmann, Peter Moccia, Alden Greil, Richard Herzberg, Mark Fosså, Alexander Hüttmann, Andreas Keil, Felix Dierlamm, Judith Schaub, Valdete Hänel, Mathias Novak, Urban Meissner, Julia Hellmuth, Johannes Mathas, Stephan Zijlstra, Josée. M. Viardot, Andreas Hertenstein, Bernd Martin, Sonja Giri, Pratush Kreissl, Stefanie Fuchs, Michael Schneider, Gundolf Rosenwald, Andreas Klapper, Wolfram Eich, Hans Theodor Baues, Christian Hallek, Michael Kobe, Carsten Diehl, Volker Engert, Andreas Hemasphere Advanced Stages Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621550/ http://dx.doi.org/10.1097/01.HS9.0000890576.23258.1c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Advanced Stages Borchmann, Peter Moccia, Alden Greil, Richard Herzberg, Mark Fosså, Alexander Hüttmann, Andreas Keil, Felix Dierlamm, Judith Schaub, Valdete Hänel, Mathias Novak, Urban Meissner, Julia Hellmuth, Johannes Mathas, Stephan Zijlstra, Josée. M. Viardot, Andreas Hertenstein, Bernd Martin, Sonja Giri, Pratush Kreissl, Stefanie Fuchs, Michael Schneider, Gundolf Rosenwald, Andreas Klapper, Wolfram Eich, Hans Theodor Baues, Christian Hallek, Michael Kobe, Carsten Diehl, Volker Engert, Andreas T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title | T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title_full | T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title_fullStr | T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title_full_unstemmed | T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title_short | T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group |
| title_sort | t002: treatment related morbidity in patients with classical hodgkin lymphoma: results of the ongoing, randomized phase iii hd21 trial by the german hodgkin study group |
| topic | Advanced Stages |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621550/ http://dx.doi.org/10.1097/01.HS9.0000890576.23258.1c |
| work_keys_str_mv | AT borchmannpeter t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT mocciaalden t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT greilrichard t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT herzbergmark t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT fossaalexander t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT huttmannandreas t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT keilfelix t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT dierlammjudith t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT schaubvaldete t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT hanelmathias t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT novakurban t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT meissnerjulia t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT hellmuthjohannes t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT mathasstephan t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT zijlstrajoseem t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT viardotandreas t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT hertensteinbernd t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT martinsonja t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT giripratush t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT kreisslstefanie t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT fuchsmichael t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT schneidergundolf t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT rosenwaldandreas t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT klapperwolfram t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT eichhanstheodor t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT baueschristian t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT hallekmichael t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT kobecarsten t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT diehlvolker t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup AT engertandreas t002treatmentrelatedmorbidityinpatientswithclassicalhodgkinlymphomaresultsoftheongoingrandomizedphaseiiihd21trialbythegermanhodgkinstudygroup |